Combining Systemic and Local/Regional Approaches to Improve Immunotherapy Sensitivity

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Immune checkpoint inhibitors (ICIs) are a cornerstone of modern cancer treatment.
• Locoregional therapies (LRTs) like radiation and targeted injections are used to control tumors locally.
• Combining ICIs with LRTs is being explored to enhance treatment efficacy.

Purpose of the Study:

• To review the evidence supporting the combination of immune checkpoint inhibition with locoregional therapies.
• To discuss the rationale behind combining these treatment modalities.
• To highlight ongoing clinical trials investigating this combination strategy.

Main Methods:

• Review of existing preclinical and clinical studies on combination therapy.
• Analysis of data from trials combining ICIs with radiation, regional perfusion, and local injections (cytokines, bacteria, viruses).
• Discussion of ongoing research and future directions.

Main Results:

• Combination therapy has demonstrated improved local tumor response in various settings.
• Systemic immune responses have been observed, particularly in patients progressing on immunotherapy prior to LRT addition.
• LRTs can potentially enhance the efficacy of ICIs by increasing tumor antigen release and modulating the tumor microenvironment.

Conclusions:

• Combining immune checkpoint inhibition with locoregional therapies is a promising strategy to improve cancer treatment outcomes.
• This combination approach can enhance both local tumor control and systemic anti-tumor immunity.
• Further research and ongoing trials are crucial to optimize this strategy for specific disease settings with significant survival or functional implications.